Kmg Fiduciary Partners 13F: Cuts AbbVie (ABBV) Stake by $623K
Kmg Fiduciary Partners reduced its stake in AbbVie Inc. by 3.8%, according to its latest 13F filing.
Reviewed by automated data checks against the source filing. How we make and check alerts
Kmg Fiduciary Partners sold 2,381 shares from its stake in AbbVie Inc. ($ABBV), a 3.77% decrease, according to a 13F filing with the SEC dated October 14, 2026. It reported 60,697 shares worth $15.88 million at the end of the quarter.
Since the filing, $ABBV is up 1.3% to date (from the $281.75 close on Oct 14, 2026).
Find the original: Kmg Fiduciary Partners 13F filings on SEC EDGAR
ABBV
AbbVie Inc.
Key Points
- Kmg Fiduciary Partners reduced its holdings in AbbVie Inc. by 2,381 shares, a decrease of 3.8%, bringing its total to 60,697 shares valued at $15.88 million.
- AbbVie Inc. has a market cap of about $467.4 billion, a P/E ratio of 74.7, and a forward P/E of 16.3, with a 52-week range between $190.75 and $267.47.
- The company pays an annual dividend of $6.92, yielding 2.62%, with a payout ratio of 1.90, and will report earnings on October 29, 2026.
Get $ABBV trade alerts by text
We text you when insiders, Congress or big funds trade $ABBV. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated AbbVie Inc. alert may contain errors. Disclosures
Kmg Fiduciary Partners has trimmed its stake in AbbVie Inc. (NYSE: ABBV), reducing its holdings by 2,381 shares. As of its latest 13F filing, the fund now holds 60,697 shares valued at approximately $15.88 million. This marks a 3.8% decrease in its position from the previous quarter.
Kmg Fiduciary Partners vs. the S&P 500
Hypothetical returns from Kmg Fiduciary Partners's disclosed trades, not real profit or advice. How we model this.
What Changed in Kmg Fiduciary Partners' AbbVie Position
Kmg Fiduciary Partners decreased its holdings in AbbVie by 3.8%, selling 2,381 shares. The fund now holds a total of 60,697 shares, down from 63,078 shares previously. The current value of these shares is about $15.88 million.
AbbVie Inc. Stock Up 0.7%
Shares of AbbVie Inc. are currently trading in a 52-week range of $190.75 to $267.47. The company, which operates in the healthcare sector, has a market capitalization of approximately $467.4 billion. It has a P/E ratio of 74.7 and a forward P/E of 16.3, indicating expectations for future earnings growth. AbbVie’s beta is 0.281, suggesting it is less volatile compared to the overall market. The stock's 50-day moving average is $255.68, while the 200-day moving average is $229.80.
Recent Earnings
AbbVie Inc. reported revenue of $64.39 billion with a growth rate of 10.2%. The company's net margin stood at 9.8%, and its earnings per share (EPS) is $3.54. Investors can look forward to the next earnings report scheduled for October 29, 2026.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
4 analysts raised price targets.
-
EPS & revenue
EPS met estimates. Revenue met estimates.
-
Profit surprise
EBITDA missed by 42 percent. Operating income missed by 72 percent.
-
Pre-earnings setup
Expectations were about average.
-
Analyst signal
4 target raises.
-
Earnings quality
Gross margin up 1.9 points. Operating margin up 3.6 points. Positive free cash flow.
Earnings Call Summary
AbbVie delivered strong first quarter results with $15 billion in sales and earnings per share of $2.65, beating expectations. Skyrizi sales hit $4.5 billion with 29 percent growth in psoriasis and inflammatory bowel disease markets. Rinvoq brought in $2.1 billion with 20 percent growth across rheumatology and gastroenterology, and the company is preparing to launch the drug in alopecia areata and vitiligo later this year.
Guidance The company raised full year earnings per share guidance to between $14.08 and $14.28, up $0.12. They now expect about $67.3 billion in total sales for the year. They also raised guidance for second quarter to about $16.7 billion in revenue and earnings per share between $3.74 and $3.78.
Fine but not compelling. Acceptable results that likely do not create a meaningful forward reset.
Dividend
AbbVie Inc. offers an attractive dividend, with an annual rate of $6.92 per share and a yield of 2.62%. The dividend payout ratio is relatively high at 1.90, reflecting the company's commitment to returning capital to shareholders.
About AbbVie Inc.
AbbVie Inc. is a global biopharmaceutical company headquartered in North Chicago, Illinois. It focuses on developing and delivering innovative medicines and therapies across various therapeutic areas, including immunology, oncology, and neuroscience. Under the leadership of CEO Scott T. Reents, AbbVie employs approximately 57,000 people worldwide. The company is known for its extensive portfolio of products, including Skyrizi, Rinvoq, Imbruvica, and Botox.
Bottom Line
The recent 13F filing by Kmg Fiduciary Partners shows a slight reduction in its AbbVie holdings, which may interest investors tracking institutional movements. While these filings provide insights into past positions, they do not necessarily reflect current or future strategies. AbbVie remains a significant player in the healthcare sector, with a strong market presence and a robust dividend offering.
Related Filing Alerts
Source: Kmg Fiduciary Partners's 13F filing on $ABBV (Oct 14, 2026). 13F filings show holdings as of the end of the reporting quarter and may not reflect the fund's current position. Find the original filing: Kmg Fiduciary Partners 13F filings on SEC EDGAR. Written by software, not financial advice. How we make alerts